Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

Medicine

Valproic Acid Concentration Drops With Ketogenic Diet

For patients with epilepsy, anti-epileptic drug serum concentrations remain stable during the ketogenic diet, apart from those of valproic acid, according to a study published online June 18 in the Journal of Clinical Pharmacy and Therapeutics. Changes in serum concentrations of other anti-epileptic drugs not found to be significant. For patients with epilepsy, anti-epileptic drug serum concentrations remain stable during the ketogenic diet (KD), apart from those of valproic acid, according to a study published online June 18 in the Journal of Clinical Pharmacy and Therapeutics.

Epilepsy and natural treatments: Can they help?

Epilepsy is a disease that disrupts the electrical activity of the nervous system, causing seizures. More than 65 million people in the world have epilepsy. 1 in 26 Americans will develop the disease during their lives. Children are the group most frequently diagnosed with new cases of epilepsy. In the United States, 300,000 children under 14 are affected by the condition. Some may outgrow the disorder, but most will not. The number of senior citizens with epilepsy is also 300,000. People with epilepsy have a range of treatment options, including alternative therapies. The illness is a complex condition, however, and all alternative treatment options must be looked at carefully, to ensure they are effective. Causes of epilepsy Epilepsy is a complex disease that can disrupt the electrical a...

In a first, marijuana substance reduces seizures for some epilepsy patients in clinical trial

For the first time, scientists have demonstrated that a component of cannabis reduces seizures in children with a rare form of epilepsy, marking a significant step in efforts to use marijuana and its derivatives to treat serious medical conditions.

High School Athlete With Epilepsy Fights to Bring CBD Oil on Campus

  A Georgia high school athlete has found himself in the middle of a medicinal cannabis debate, as school officials refuse to let the student, who suffers from epilepsy, take his medicinal cannabis oil on campus at lunch.

Epilepsy Seizure Treatment Trobalt to Be Discontinued in June 2017

GlaxoSmithkline (GSK) announced that its epilepsy seizure drug Trobalt (retigabine) will no longer be commercially available after June 2017. The company has advised healthcare providers to seek alternative medicines for patients as soon as possible and ensure that all patients are withdrawn from Trobalt by the end of June.

USFDA rejects SPARC’s epilepsy drug application

The US health regulator has denied approval to Sun Pharma Advanced Research Company’s (SPARC) new drug application for Elepsia XR, an anti-epileptic drug. The company has received a Complete Response Letter (CRL) from the USFDA for its new drug application for Elepsia XR, Levetiracetam extended-release tablets in strengths of 1,000 mg and 1,500 mg, SPARC said in a regulatory filing.

University of Warwick research focuses on absence epilepsy that affects children

A University of Warwick study to understand a form of epilepsy that affects children has received a grant from the charity Epilepsy Research UK. The research focuses on absence epilepsy which is largely a childhood condition which is characterized by sudden, brief interruptions of consciousness. In severe cases there may be more than 200 of these episodes each day, and these can be accompanied by or develop into convulsive seizures. Many children with absence seizures don’t respond to existing antiepileptic medication, which can present numerous difficulties in daily life, particularly with schooling.

Protein Found That May Improve Epilepsy Patients’ Response to Therapies

A protein that may help epilepsy patients respond better to drug therapies has been identified, a new study suggests. The study, titled “Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy,” was published in the The Journal of Clinical Investigation.

Lawmakers push legislation to provide epilepsy treatment nationwide

A controversial treatment for children with severe epilepsy could become legal nationwide. The treatment uses oil derived from Marijuana. While the treatment is legal in 44 states across the country, the treatment is still a challenge for many to access. Charlotte Figi, 10, is a happy and healthy third-grader from Colorado Springs. It’s a sight, mother, Paige Figi says she thought she’d never witness. Five and a half years ago, she was preparing to say goodbye.

Why some images trigger seizures

In people with photosensitive epilepsy, flashing lights are well known for their potential to trigger seizures. The results can be quite stunning. For instance, a particular episode of Pokémon sent 685 people in Japan to the hospital. But seizures can be triggered by certain still images, too. Now, researchers reporting in Current Biology on May 8 who have conducted an extensive review of the scientific literature think they know what it is about some static pictures that can trigger seizures.

Members of Congress and Senate in Support of the New CBD Bill

 Known as the Therapeutic Hemp Medical Access Act, a bipartisan bill introduced this week seeks to ensure unrestricted access to specific strains high in CBD for individuals battling intractable epilepsy. Requesting an exemption from the Controlled Substance Act (CSA) for “strains of therapeutic hemp” known to be high in Cannabidiol (CBD), the bill was announced and endorsed by nine state senators on Tuesday.

Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

The U.S. Food and Drug Administration has granted Orphan Drug Designation to EPX-100 and EPX-200 for the treatment of patients with Dravet syndrome. Dravet Syndrome qualifies as a rare pediatric disease under Section 529 of Food, Drug, and Cosmetic Act. The rare, catastrophic, lifelong form of epilepsy begins in the first year of life with frequent or prolonged seizures. Intellectual disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are commonly observed as the disease progresses. Patients with Dravet Syndrome also suffer with life-threatening seizures that cannot be adequately controlled by available medications, and face a 15-20 percent mortality rate due to SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, o...

Lost Password

Register